Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
Momenta Phama (MNTA) Tops Q2 EPS by 20c
May 2, 2017 8:02 AM EDTMomenta Phama (NASDAQ: MNTA) reported Q2 EPS of ($0.46), $0.20 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $23.4 million versus the consensus estimate of $24.49 million.
Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same... More